Pluri (PLUR) Short term Debt (2018 - 2025)

Pluri (PLUR) reported Short term Debt of $27.8 million for Q4 2025, up 0.88% quarter-over-quarter from $27.5 million in Q3 2025.

Pluri (PLUR) Short term Debt (2018 - 2025) Analysis & Trends

Pluri (PLUR) has 2 years of Short term Debt data on file, last reported at $27.8 million in Q4 2025.

Short term Debt for Q4 2025 came in at $27.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $27.8 million (changed N/A YoY), and the FY2025 annual result was $27.3 million, changed N/A from the prior year.
Short term Debt improved to $27.8 million in Q4 2025 per PLUR's latest filing, from $27.5 million in the prior quarter.
Over five years, Short term Debt peaked at $27.8 million in Q4 2025 and troughed at $27.3 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Pluri	21.39 Mn	21.87 Mn	86,000.00

Download Data